"id","label","uuid:ID","name","instanceType","description","rationale"
"StudyDesign_1","","8fe53782-ab4d-4a66-a1d1-78744dc510de","Study Design 1","StudyDesign","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
